Opendata, web and dolomites

MITOPOMPE SIGNED

Targeting mitochondrial defects and oxidative stress in Pompe Disease: from pathogenesis to therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MITOPOMPE project word cloud

Explore the words cloud of the MITOPOMPE project. It provides you a very rough idea of what is the project "MITOPOMPE" about.

buffering    perform    disease    tissues    alpha    atp    pathology    interacting    calcium    neuron    sequencing    group    extensive    pompe    interventions    dr    function    rna    transmission    antioxidants    brain    muscular    mitoq    mtgsh    gaa    mutations    dependent    acid    model    aav    phenotypes    severity    tested    treatment    muscle    expertise    fighting    cardiomyopathy    signaling    disorders    oxidative    reversal    ko    lysosomal    enzyme    involvement    cellular    treat    functional    depending    gene    synapses    regulated    nervous    organelle    rescue    lsd    stress    little    central    cell    respiratory    pd    lsds    potentially    synaptic    competent    storage    motor    evident    accordingly    phosphorylation    therapeutic    glucosidase    mitochondria    pharmaceutical    transcriptomic    apoptosis    pathophysiology    weakness    dysfunction    amounts    combined    defects    therapy    everyday    mitochondrial    active    therapies    nrf2    heavily    full    point    complemented    neurological    neuromuscular    functionally    mitocatalase    mouse    missing    avenues    caused    neuronal    boost    mingozzi   

Project "MITOPOMPE" data sheet

The following table provides information about the project.

Coordinator
ASSOCIATION GENETHON 

Organization address
address: RUE DE L INTERNATIONALE 1 BIS
city: EVRY
postcode: 91002
website: www.genethon.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 173˙076 €
 EC max contribution 173˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSOCIATION GENETHON FR (EVRY) coordinator 173˙076.00

Map

 Project objective

The central role of ATP production by oxidative-phosphorylation, together with calcium buffering and apoptosis, makes mitochondria an organelle interacting with many processes within the cell. Neuronal and muscular tissues require high amounts of ATP to perform their everyday function, therefore are heavily dependent on mitochondrial function. Neuromuscular synapses are of particular importance since synaptic transmission is a highly regulated process which requires active and functionally competent mitochondria. Accordingly, mitochondrial involvement is becoming increasingly evident in is Lysosomal Storage Disorders (LSDs) along with neurological pathology. Over the past several years Dr. Mingozzi’s group has built extensive expertise in Pompe Disease (PD), an LSD which is caused by mutations in the enzyme acid α-glucosidase (GAA). Muscle weakness, cardiomyopathy, respiratory failure, central nervous system and more specifically motor-neuron defects are observed depending on the severity of the disease. Little is known about the role of mitochondria in the pathophysiology of PD and interventions aimed at addressing mitochondrial defects in PD is currently missing. The aim of this proposal is to characterize the mitochondrial dysfunction in the Gaa KO mouse model of PD. This to assess potential rescue of such phenotypes by AAV-based GAA gene therapy complemented with therapeutic interventions targeted to treat and boost mitochondrial function by fighting against oxidative stress. Two mitochondrial treatment approaches; (i) pharmaceutical antioxidants, e.g. mitoQ or mtGSH and (ii) AAV based approaches; AAV-Nrf2 and AAV-mitoCatalase will be tested. Combined therapies with the AAV-GAA treatment will aim to reach full rescue of the muscle and brain pathology and functional reversal of mitochondrial defects. Transcriptomic changes will also be analyzed by RNA sequencing to investigate cellular signaling changes which will potentially point to novel therapeutic avenues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MITOPOMPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MITOPOMPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

INFORM (2020)

Innovative Electrochemical Multiplex Biosensor for Detection and Quantification of Clinically Relevant Circulating miRNAs

Read More  

LYSOKIN (2020)

Architecture and regulation of PI3KC2β lipid kinase complex for nutrient signaling at the lysosome

Read More  

COMBATTB (2019)

Comprehensive Mechanisms of Bacterial Antibiotic Tolerance in Mycobacterium Tuberculosis

Read More